Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison

Clinical Therapeutics

Volumn 29, Issue 6 PART 1, 2007, Pages 1254-1270

  Ilag, Liza L ^a   Kerr, Lisa ^a   Malone, James K ^a   Tan, Meng H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

aspart; glargine; lispro; premixed insulin analogue; type 2 diabetes

Indexed keywords

HUMALOG MIX 50/50; HUMALOG MIX 75/25; HUMALOG MIX25; HUMALOG MIX50; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LEVIMIR; METFORMIN; NOVOLOG MIX 70/30; PIOGLITAZONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GLARGINE; INSULIN; INSULIN, ASP(B28)-;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38449093271     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.003     Document Type: Article

References (63)

1. Owens D., Zinman B., and Bolli G. Insulins today and beyond. [published correction appears in Lancet. 2001;358:1374]. Lancet 358 (2001) 739-746
2. Schade D., and Eaton R. A clinician's guide to subcutaneous insulin infusion based on the kinetics of insulin absorption from subcutaneous tissue. In: Peterson C. (Ed). Diabetes Management in the '80s: The Role of Home Blood Glucose Monitoring and New Insulin Delivery Systems (1982), NY: Praeger, New York 110-115
3. Perley M., and Kipnis D. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J Clin Invest 46 (1967) 1954-1962
4. Ward W., Bolgiano D., McKnight B., et al. Diminished B cell secretory capaciW in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74 (1984) 1318-1328
5. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
6. AACE. Diabetes Guidelines. Endocr Pract. 8 Suppl 1 (2002) 43-65
7. International Diabetes Federation. Global guideline for type 2 diabetes.
8. Available at:. http://www.idf.org/home/ index.cfm? node =1457 Accessed January 31, 2007
9. Hirsch I., Bergenstal R., Parkin C., et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 23 (2005) 78-86
10. Skyler J. Insulin treatment. In: Lebovitz H. (Ed). Therapy for Diabetes Mellitus and Related Disorders. 3 (1998), American Diabetes Association, Alexandria, Va 186-203
11. Rolla A., and Rakel R. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 27 (2005) 1113-1125
12. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 66 (2006) 31-49
13. Halimi S., Raskin P., Liebl A., et al. Efficacy ofbiphasic insulin aspart in patients with Type 2 diabetes. Clin Ther 27 Suppl B (2005) S57-S74
14. Naiker P., Makan H., Omar M., et al., for the BIAsp-1579 Study Group. Effect ofbiphasic insulin aspart 30/70 in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents. Diabetologia 49 Suppl 1 (2006) 599-600 Abstract
15. Holcombe J., Zagar A., Pinaire J., Prince M., and for the IOMN Study Group. Superiority of insulin lispro 75/25 compared with NPH when used in combination with metformin. Diabetes 51 Suppl 2 (2002) A101 Abstract
16. Kilo C., Mezitis N., Jain R., et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 17 (2003) 307-313
17. Garber A., Wahlen J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 8 (2006) 58-66
18. Raskin P., Allen E., Hollander P., et al., for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
19. Malone J., Kerr L., Campaigne B., et al., for the Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. [published correction appears in Clin Ther. 2005;27:1112]. Clin Ther. 26 (2004) 2034-2044
20. Malone J., Bai S., Campaigne B., et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 22 (2005) 374-381
21. Service F., O'Brien P., and Rizza R. Measurements of glucose control. Diabetes Care 10 (1987) 225-237
22. Roach P., and Malone J. Comparison of insulin lispro mixture 75/25 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med 23 (2006) 743-749
23. Valentine W., Palmer A., Lammert M., et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: Cost-effectiveness analysis in the UK setting. Curr Med Res Opin 21 (2005) 2063-2071
24. Ejskjaer N., Rasmussen M., Kamp N., et al. Comparison of thrice-daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab 5 (2003) 438-445
25. Lund S., Tarnow L., Nielsen B., et al. Effect of BiAsp 30 (biphasic insulin aspart 30) in combination with oral hypoglycaemic agents on glycaemic regulation in non-obese patients with type 2 diabetes. Diabetologia 49 Suppl 1 (2006) 600 Abstract
26. Ligthelm R., Mouritzen U., Lynggaard H., et al. Biphasic insulin aspart thrice-daily is as efficacious as traditional basal bolus regimen with four daily injections in subjects with type 2 diabetes. Diabetes 54 Suppl 1 (2005) A122-A123 Abstract
27. Ligthelm R., Mouritzen U., Lynggaard H., et al. Biphasic insulin aspart given thrice-daily is as efficacious as a conventional basal bolus insulin regimen with four daily injections in subjects with type 2 diabetes. Diabetologia 48 Suppl 1 (2005) A311 Abstract
28. Jacober S., Scism-Bacon J., and Zagar A. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 8 (2006) 448-455
29. Kazda C., Hulstrunk H., Helsberg K., et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 20 (2006) 145-152
30. Robbins D., Beisswenger P., Ceriello A., et al. Thrice-daily lispro mid mixture plus metformin improved glycemic control better than glargine plus metformin in patients with type 2 diabetes. Diabetes 55 Suppl 1 (2006) 554-P A132. Abstract
31. lc and blood glucose profiles in patients with type 2 diabetes. Diabetologia 49 Suppl 1 (2006) 603-604 Abstract
32. Riddle M., Rosenstock J., Gerich J., and For the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
33. Davies M., Storms F., Shutler S., et al., For the ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
34. lc target <7.0%. Diabetologia 49 Suppl 1 (2006) 610-611 Abstract
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
36. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 28 (1995) 103-117
37. Wright A., Burden A., Paisey R., et al., For the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). [published correction appears in Diabetes Care. 2002;25:1268]. Diabetes Care 25 (2002) 330-336
38. Turner R., Cull C., Frighi V., Holman R., and for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonyl-urea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
39. DeWitt D., and Hirsch I. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
40. Mooradian A., Bernbaum M., and Albert S. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med. 145 (2006) 125-134
41. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Associations For the Study of Diabetes. [published correction appears in Diabetes Care. 2006;49:2816-2818]. Diabetes Care 29 (2006) 1963-1972
42. Heine R., Diamant M., Mbanya J., and Nathan D. Management of hyperglycaemia in type 2 diabetes: The end of recurrent failure?. BMJ 333 (2006) 1200-1204
43. Ryden L., Standl E., Bartnik M., et al., for the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association For the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. Eur Heart J 28 (2007) 88-136
44. Bloomgarden Z. Achieving glycemic goals in type 2 diabetes. Diabetes Care 30 (2007) 174-180
45. In: Kelley D. (Ed). Medical Management of Type 2 Diabetes. 4 (1998), American Diabetes Association, Alexandria, Va
46. In: Pawson D. (Ed). Triple I Endocrinology Prescribing Guide, Fall 2006/Winter 2007 (2006), MediMedia USA, Inc, Carlstadt, NJ
47. Erlinger T., and Brancati F. Post-challenge hyperglycemia in a national sample of US adults with type 2 diabetes. [published correction appears in Diabetes Care. 2002;25:249]. Diabetes Care 24 (2001) 1734-1738
48. Oiknine R., Bernbaum M., and Mooradian A. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 65 (2005) 325-340
49. Hirsch I. Insulin analogues. N Engl J Med 352 (2005) 174-183
50. Roach P., Arora V., Campaigne B., et al., For the India Mix25/Mix50 Study Group. Humalog Mix 50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 5 (2003) 311-316
51. Comparing pre-mixed insulin with insulin glargine combined with rapid-acting insulin in patients with type 2 diabetes.
52. Available at:. http://www.clinicaltrials.gov/ct/show/NCT00110370 Accessed February 5, 2007
53. Monnier L., Lapinski H., and Colette C. Contribution of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
54. Farmer A., Thorne K., Stratton I., et al. Treating to Target in Type 2 Diabetes (4-T): Study of analogue insulin initiation and titration. Diabetes 55 Suppl 1 (2006) A474 Abstract
55. 4-T (Treating to Target in Type 2 Diabetes) study. Overview.
56. Available at:. http://www.dtu.ox.ac.uk/4-T/overview.php Accessed February 5, 2007
57. The DURABLE trial: Evaluating the durability of starter insulin regimens in patients with type 2 diabetes.
58. Available at:. http://www.clinicaltrials.gov//ct/show/NCTO0279201 Accessed February 5, 2007
59. Nauck M., Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologla 50 (2007) 259-267
60. Biesenbach G., Bodlaj G., and Pieringer H. Weight gain and metabolic control in newly insulin-treated patients with type 2 diabetes with different insulin regimens. Can J Diabetes 30 (2006) 384-389
61. Davidson M. Starting insulin therapy in type 2 diabetic patients: Does it really matter how?. Diabetes Care 28 (2005) 494-495
62. Rubino A., McQuay L., Kvasz M., and Tennis P. Population-based study of time to insulin after failure of oral antidiabetic (OA) therapy in type 2 diabetes in the UK. Diabetes 55 Suppl 1 (2006) A76 Abstract
63. Nichols G., Koo Y., and Menditto L. Delay in treatment escalation when glycemic control is not maintained on oral combination therapy. Diabetes 55 Suppl 1 (2006) A127 Abstract